<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2025-8-3-92-108</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-470</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНТЕРВЕНЦИОННАЯ РАДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERVENTIONAL RADIOLOGY</subject></subj-group></article-categories><title-group><article-title>Химиоэмболизация источников экстрапеченочного кровоснабжения при злокачественных опухолях печени: опыт 126 вмешательств, выполненных на базе одного центра</article-title><trans-title-group xml:lang="en"><trans-title>Chemoembolization for Malignant Hepatic Tumors Supplied by Extrahepatic Feeders: Single-Center Experience of 126 Interventions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-5656-4426</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акинфеев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Akinfeyev</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Владимирович Акинфеев, +375 29 7583034 </p><p>223040 Минский район, аг. Лесной </p></bio><bio xml:lang="en"><p>Vladimir V. Akinfeyev </p><p>223040 Lesnoy, Minsk district </p></bio><email xlink:type="simple">vladimirakin@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орехов</surname><given-names>В. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Orekhov</surname><given-names>V. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>223040 Минский район, аг. Лесной </p></bio><bio xml:lang="en"><p>Vitaly F. Orekhov </p><p>223040 Lesnoy, Minsk district </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский научно-практический центр онкологии и медицинской радиологии им. Н. Н. Александрова»</institution><country>Беларусь</country></aff><aff xml:lang="en"><institution>N. N. Alexandrov National Cancer Centre of Belarus</institution><country>Belarus</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>09</month><year>2025</year></pub-date><volume>8</volume><issue>3</issue><fpage>92</fpage><lpage>108</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Акинфеев В.В., Орехов В.Ф., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Акинфеев В.В., Орехов В.Ф.</copyright-holder><copyright-holder xml:lang="en">Akinfeyev V.V., Orekhov V.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/470">https://www.oncoradjournal.ru/jour/article/view/470</self-uri><abstract><p>Цель: Представить опыт выполнения химиоэмболизаций экстрапеченочных источников кровоснабжения злокачественных опухолей печени выполненных на базе одного онкологического центра.Материалы и методы: У 69 пациентов с гепатоцеллюлярным раком (ГЦР) и другими злокачественными опухолями печени выполнено 126 трансартериальных химиоэмболизаций экстрапеченочных артерий, участвующих в кровоснабжении опухолей. В 77 (61,9 %) случаях при химиоэмболизации использовались микросферы, выделяющие химиопрепарат (DEM‑TACE), в 45(35,7 %) выполнялась традиционная химиоэмболизация эмульсией липиодола и химиопрепарата (cTACE) и в 4 (3,2 %) эмболизационным агентом были микросферы без химиопрепарата. В 78(61,9 %) случаях трансартериальная химиоэмболизация экстрапеченочных источников кровоснабжения (ТАХЭ ЭИК) опухолей выполнялась одновременно с трансартериальной химиоэмболизацией ветвей печеночной артерии (ТАХЭ ПА). ТАХЭ одного ЭИК осуществлена в 100 (79,4 %), двух — в 24 (19 %) и трех — в 2(1,6 %) случаях. Источниками экстрапеченочного кровоснабжения опухолей были ветви следующих артерий: правая нижняя диафрагмальная — 71(56,3 %), пузырная — 23(18,3 %), 18(14,3 %) — сальниковая, 10(7,9 %) — нижние правые межреберные, 7(5,6 %) — левая нижняя диафрагмальная, 4(3,2 %) — правая и левая внутренние грудные , 4 (3,2 %) — желудочно-двенадцатиперстная, 3(2,4 %) — левая желудочная, 3(2,4 %) — верхняя брыжеечная артерия, 3(2,4 %) — капсулярная правой почки, 3(2,4 %) — правая нижняя надпочечниковая, 1(1,6 %) — правая средняя надпочечниковая и 1(1,6 %) — первая правая поясничная артерия.Результаты и обсуждение: После ТАХЭ ЭИК опухолей печени было 14(11,1 %) осложнений. Выраженный болевой синдром с иррадиацией боли в правое надплечье после ТАХЭ правой нижней диафрагмальной артерии наблюдался 10 раз (3a степень — 6, 2 степень — 4, по классификации CIRSE), перманентная эритема кожи в зоне кровоснабжения артерий — 4 раза (4 степень по CIRSE) после ТАХЭ ветвей правых межреберных, правой внутренней грудной артерии и левой желудочной артерии. У 36 пациентов с ГЦР, лечившихся только методом ТАХЭ, показатели общей выживаемости от момента первой ТАХЭ ЭИК составили: медиана 13,7 месяцев, 6-месячная выживаемость — 72,2±7,5 %, 1-годичная — 55,6±8,3 %, 2-летняя — 26,7±7,5 %, 3-летняя — 17,8±6,5 % и 5-летняя — 11,9±5,5 %. Медиана общей выживаемости от момента первой ТАХЭ составила 20,9 месяцев, 6-месячная выживаемость — 77,8±6,9 %, 1-годичная — 72,2±7,5 %, 2-летняя — 38,9±8,1 %, 3-летняя — 30,6±7,7 % и 5-летняя — 18,5±6,6 %. На основании собственного опыта и данных литературы проведен обзор всех возможных осложнений и способов по их минимизации. Рассмотрены причины возникновения экстрапеченочного кровоснабжения и методы диагностики. Акцент сделан на возможность проведения не только cTACE, но и DEM‑TACE. Особенностью нашей работы явилось относительно большое число пациентов с метастазами в печени, в отличие от литературных данных, основанных на анализе результатов лечения только ГЦР.Заключение: Экстрапеченочное кровоснабжение опухолей печени часто встречается при опухолях большого размера, периферической локализации и после повторных ТАХЭ, может наблюдаться не только при ГЦР, но и при других злокачественных опухолях печени, в том числе и гиповаскулярных. ТАХЭ ЭИК позволяет продолжить лечение опухолей печени эндоваскулярным методом и улучшить результаты лечения.</p></abstract><trans-abstract xml:lang="en"><p>Purpose: To present the experience of chemoembolizations of extrahepatic feeders to malignant hepatic tumors performed in a single oncological center.Materials and methods: One hundred and twenty six transarterial chemoembolizations(TACE) were performed in 69 patients with hepatocellular carcinoma (HCC) and other malignant hepatic tumors. Chemoembolization with drug-eluting microspheres (DEMTACE) was performed in 77 (61.9 %) cases, conventional chemoembolization with lipiodol/chemotherapeutic drug emulsion (cTACE) in 45(35.7 %) and bland embolization in 4(3.2 %). TACE of extrahepatic feeders (TACE EHF) was carried out with TACE of hepatic artery branches at the same session in 78(61.9 %) cases. TACE of single EHF was performed in 100 (79.4 %) cases, two feeders in 24(19 %) and three in 2(1.6 %). The branches of following arteries were EHF to the tumors: inferior phrenic artery 71(56.3 %), cystic artery — 23(18.3 %), omental branch from the gastroepiploic artery –18(14.3 %), inferior right intercostal arteries — 10(7.9 %), left inferior phrenic artery — 7(5.6 %), right and left internal thoracic arteries — 4(3.2 %), gastroduodenal artery — 4(3.2 %), left gastric artery — 3(2.4 %), superior mesenteric artery — 3(2.4 %), right renal capsular artery — 3(2.4 %), right inferior adrenal artery — 3(2.4 %), right middle adrenal artery — 1(1.6 %) and right first lumbar artery — 1(1.6 %) case.Results and discussion: After TACE EHF to hepatic tumors 14(11.1 %) complications occurred. Severe pain with irradiation to the right shoulder was observed in 10 procedures after TACE of the inferior phrenic artery (Grade 3 a — 6, Grade 2 — 4 cases according to CIRSE Classification System for Complications). Permanent skin erythema in the area supplying by an artery (grade 4) took place in 4 cases after TACE of the right intercostal arteries, right internal thoracic artery and left gastric artery branches. In the group of 36 patients with HCC treated only by TACE median overall survival from the time of first TACE EHF was 13.7 months, overall cumulative survival rates were 72.2±7.5 % (at 6 months), 55.6±8.3 % (at 1 year), 26.7±7.5 % (at 2 years), 17.8±6.5 % (at 3 years), 11.9±5.5 % (at 5 years). Median overall survival from the time of first TACE was 20.9 months, overall cumulative survival rates were 77.8±6.9 % (at 6 months), 72.2±7.5 % (at 1 year), 38.9±8.1 % (at 2 years), 30.6±7.7 % (at 3 years), 18.5±6.6 % (at 5 years). Based on own experience and literature data a review of all possible complications and techniques to avoid its was performed. Causes and imaging of extrahepatic blood supply were observed. The possibility to perform not only cTACE but DEM-TACE too was emphasized. The feature of our group was the presence of a relatively large number of patients with hepatic metastases in contrast to literature data based on analysis of treatment outcomes only of HCC.Conclusion: Extrahepatic blood supply to hepatic tumors is frequently encountered in large tumors, peripherally located tumors and after repeated TACE. It can be observed not only in HCC but in other hepatic tumors even hypovascular ones. TACE EHF allows to continue endovascular management of hepatic tumors and to improve treatment outcomes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гепатоцелюлярный рак</kwd><kwd>злокачественные опухоли печени</kwd><kwd>химиоэмболизация</kwd><kwd>экстрапеченочное кровоснабжение</kwd><kwd>паразитическое кровоснабжение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepatocellular carcinoma</kwd><kwd>malignant hepatic tumors</kwd><kwd>chemoembolization</kwd><kwd>extrahepatic blood supply</kwd><kwd>parasitic blood supply</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн АД, Старинский ВВ, Шахзадова АО. Злокачественные новообразования в России в 2023 г. (заболеваемость и смертность) — М.: МНИОИ им. П.А. Герцена, 2024.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinskiy VV, Shakhzadova AO. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Moscow, 2024 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Океанов АЕ, Моисеев ПИ, Левин ЛФ и др. Рак в Беларуси: Цифры и факты. Анализ данных Белорусского канцеррегистра за 2014–2023 гг. — Минск: Государственное учреждение «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова», — 2024.</mixed-citation><mixed-citation xml:lang="en">Okeanov AE, Moiseev PI, Levin LF, et al. Cancer in Belarus: Figures and facts. Analysis of data of Belarusian cancer register for 2014-2023. Minsk, N. N. Alexandrov National Cancer Centre of Belarus, 2024 . (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834. PMID: 38572751.</mixed-citation><mixed-citation xml:lang="en">Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834. PMID: 38572751.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.hep.2021.11.018. PMID: 34801630.</mixed-citation><mixed-citation xml:lang="en">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. https://doi.org/10.1016/j.hep.2021.11.018. PMID: 34801630.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lucatelli P, Burrel M, Guiu B, et al. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851-67. https://doi.org/10.1007/s00270-021-02968-1. PMID: 34694454.</mixed-citation><mixed-citation xml:lang="en">Lucatelli P, Burrel M, Guiu B, et al. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851-67. https://doi.org/10.1007/s00270-021-02968-1. PMID: 34694454.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sprayregen S. Parasitic Blood Supply of Neoplasms. Mechanisms and significance. Radiology. 1973;106(3):529-35. https://doi.org/10.1148/106.3.529. PMID: 4346370.</mixed-citation><mixed-citation xml:lang="en">Sprayregen S. Parasitic Blood Supply of Neoplasms. Mechanisms and significance. Radiology. 1973;106(3):529-35. https://doi.org/10.1148/106.3.529. PMID: 4346370.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lamarque JL, Triby X, Bruel JM, et al. The parasitic blood supply of abdominal masses. Eur J Radiol. 1981:1(2):104-13. PMID: 7338230.</mixed-citation><mixed-citation xml:lang="en">Lamarque JL, Triby X, Bruel JM, et al. The parasitic blood supply of abdominal masses. Eur J Radiol. 1981:1(2):104-13. PMID: 7338230.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Skezas NN, Spigos DE, Dunne PM, Langer BG. Parasitization by hepatocellular carcinoma of branches of superior mesenteric artery. AJR Am J Roentgenol. 1991;157(6):1357-8. https://doi.org/10.2214/ajr.157.6.1659163. PMID: 1659163.</mixed-citation><mixed-citation xml:lang="en">Skezas NN, Spigos DE, Dunne PM, Langer BG. Parasitization by hepatocellular carcinoma of branches of superior mesenteric artery. AJR Am J Roentgenol. 1991;157(6):1357-8. https://doi.org/10.2214/ajr.157.6.1659163. PMID: 1659163.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, Lee W, et al. Recognizing Extrahepatic Collateral Vessels That Supply Hepatocellular Carcinoma to Avoid Complications of Transcatheter Arterial Chemoembolization. Radiographics. 2005;25 Suppl 1:S25-39. https://doi.org/10.1148/rg.25si055508. PMID: 16227494.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, Lee W, et al. Recognizing Extrahepatic Collateral Vessels That Supply Hepatocellular Carcinoma to Avoid Complications of Transcatheter Arterial Chemoembolization. Radiographics. 2005;25 Suppl 1:S25-39. https://doi.org/10.1148/rg.25si055508. PMID: 16227494.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Miyayama S, Masui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 2006;29(1):39-48. https://doi.org/10.1007/s00270-004-0287-y. PMID: 16328697.</mixed-citation><mixed-citation xml:lang="en">Miyayama S, Masui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 2006;29(1):39-48. https://doi.org/10.1007/s00270-004-0287-y. PMID: 16328697.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Miyayama S, Yamashiro M, Okuda M, et al. Creation of a Cleft in an Angiography Catheter to Facilitate Catheterization of Branches of the Aorta Arising at an Acute Angle. J Vasc Interv Radiol. 2008;19(12):1769-71. https://doi.org/10.1016/j.jvir.2008.08.024. PMID: 18845456.</mixed-citation><mixed-citation xml:lang="en">Miyayama S, Yamashiro M, Okuda M, et al. Creation of a Cleft in an Angiography Catheter to Facilitate Catheterization of Branches of the Aorta Arising at an Acute Angle. J Vasc Interv Radiol. 2008;19(12):1769-71. https://doi.org/10.1016/j.jvir.2008.08.024. PMID: 18845456.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Filippiadis DK, Binkert C, Pellerin O, et al. Cirse Quality Assurance Document and Standarts for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017;40(8):1141-6. https://doi.org/10.1007/s002270-017-1703-4. PMID: 28584945.</mixed-citation><mixed-citation xml:lang="en">Filippiadis DK, Binkert C, Pellerin O, et al. Cirse Quality Assurance Document and Standarts for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017;40(8):1141-6. https://doi.org/10.1007/s002270-017-1703-4. PMID: 28584945.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe Y, Tokue H, Taketomi-Takahashi A, Tsushima Y. Imaging findings and complications of transcatheter treatments via the inferior phrenic arteries in patients with hepatocellular carcinoma. Eur J Radiol Open. 2018;5:171-6. https://doi.org/10.1016/j.ejro.2018.08.010. PMID: 30263910.</mixed-citation><mixed-citation xml:lang="en">Watanabe Y, Tokue H, Taketomi-Takahashi A, Tsushima Y. Imaging findings and complications of transcatheter treatments via the inferior phrenic arteries in patients with hepatocellular carcinoma. Eur J Radiol Open. 2018;5:171-6. https://doi.org/10.1016/j.ejro.2018.08.010. PMID: 30263910.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Shin SW, Do YS, Choo SW, et al. Diaphragmatic weakness after Transcatheter Arterial Chemoembolization of Inferior Phrenic Artery for Treatment of Hepatocellular Carcinoma. Radiology. 2006;241(2):581-8. https://doi.org/10.1148/radiol.2412051209. PMID: 17005772.</mixed-citation><mixed-citation xml:lang="en">Shin SW, Do YS, Choo SW, et al. Diaphragmatic weakness after Transcatheter Arterial Chemoembolization of Inferior Phrenic Artery for Treatment of Hepatocellular Carcinoma. Radiology. 2006;241(2):581-8. https://doi.org/10.1148/radiol.2412051209. PMID: 17005772.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lee DH, Chung JW, Kim H-C, et al. Development of diaphragmatic weakness after transcatheter arterial chemoembolization of the right inferior phrenic artery: frequency and determinant factors. J Vasc Interv Radiol. 2009;20(4):484-9. https://doi.org/10.1016/j.jvir.2008.11.023. PMID: 19157895.</mixed-citation><mixed-citation xml:lang="en">Lee DH, Chung JW, Kim H-C, et al. Development of diaphragmatic weakness after transcatheter arterial chemoembolization of the right inferior phrenic artery: frequency and determinant factors. J Vasc Interv Radiol. 2009;20(4):484-9. https://doi.org/10.1016/j.jvir.2008.11.023. PMID: 19157895.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt1):893-900. https://doi.org/10.1016/s1051-0443(07)61772-2.</mixed-citation><mixed-citation xml:lang="en">Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt1):893-900. https://doi.org/10.1016/s1051-0443(07)61772-2.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kim JS, Lee HN, Lee WH, Bae SH. Diaphragmatic perforation after transcatheter arterial chemoembolization of hepatocellular carcinoma via inferior phrenic artery: a case report. BMC Gastroenterology. 2022;22(1):46. https://doi.org/10.1186/s12876-022-02110-6. PMID: 35123408.</mixed-citation><mixed-citation xml:lang="en">Kim JS, Lee HN, Lee WH, Bae SH. Diaphragmatic perforation after transcatheter arterial chemoembolization of hepatocellular carcinoma via inferior phrenic artery: a case report. BMC Gastroenterology. 2022;22(1):46. https://doi.org/10.1186/s12876-022-02110-6. PMID: 35123408.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z, Ni R-f, Busireddy KKR, et al. Cerebral embolism following transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of two cases and literature review. Chin Med J(Engl). 2011;124(24):4355-8. PMID: 22340413.</mixed-citation><mixed-citation xml:lang="en">Li Z, Ni R-f, Busireddy KKR, et al. Cerebral embolism following transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of two cases and literature review. Chin Med J(Engl). 2011;124(24):4355-8. PMID: 22340413.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Suh SH, Won JY, Lee DY, et al. Chemoembolization of the left inferior phrenic artery in patients with hepatocellular carcinoma radiographic findings and clinical outcome. J Vasc Interv Radiol. 2005;16(12):1741-5. https://doi.org/10.1097/01.RVI.0000182172.00168.1B. PMID: 16371544.</mixed-citation><mixed-citation xml:lang="en">Suh SH, Won JY, Lee DY, et al. Chemoembolization of the left inferior phrenic artery in patients with hepatocellular carcinoma radiographic findings and clinical outcome. J Vasc Interv Radiol. 2005;16(12):1741-5. https://doi.org/10.1097/01.RVI.0000182172.00168.1B. PMID: 16371544.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, Kim WH, et al. Chemoembolization of the left inferior phrenic artery in patients with hepatocellular carcinoma: 9-year single-center experience. AJR Am J Roentgenol. 2010;194(4):1124-30. https://doi.org/10.2214/AJR.09.3030. PMID: 20308531.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, Kim WH, et al. Chemoembolization of the left inferior phrenic artery in patients with hepatocellular carcinoma: 9-year single-center experience. AJR Am J Roentgenol. 2010;194(4):1124-30. https://doi.org/10.2214/AJR.09.3030. PMID: 20308531.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Arora R, Soulen MC, Haskal ZJ. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol. 1999;10(10):1351-6. https://doi.org/10.1016/s1051-0443(99)70242-3. PMID: 10584650.</mixed-citation><mixed-citation xml:lang="en">Arora R, Soulen MC, Haskal ZJ. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol. 1999;10(10):1351-6. https://doi.org/10.1016/s1051-0443(99)70242-3. PMID: 10584650.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kajiwara K, Kakizawa H, Takeuchi N, et al. Cutaneous complications after transcatheter arterial treatment for hepatocellular carcinoma via the internal mammary artery: how to avoid this complication. Jpn J Radiol. 2011;29(5):307-15. https://doi.org/10.1007/s11604-011-0559-9. PMID: 21717298.</mixed-citation><mixed-citation xml:lang="en">Kajiwara K, Kakizawa H, Takeuchi N, et al. Cutaneous complications after transcatheter arterial treatment for hepatocellular carcinoma via the internal mammary artery: how to avoid this complication. Jpn J Radiol. 2011;29(5):307-15. https://doi.org/10.1007/s11604-011-0559-9. PMID: 21717298.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, Choi SH, et al. Hepatocellular Carcinoma with Internal Mammary Artery Supply: Feasibility and Efficasy of Transarterial Chemoembolization and Factors Affecting Patients Prognosis. J Vasc Interv Radiol. 2007;18(5):611-9;quiz 620. https://doi.org/10.1016/j.jvir.2007.02.023. PMID: 17494842.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, Choi SH, et al. Hepatocellular Carcinoma with Internal Mammary Artery Supply: Feasibility and Efficasy of Transarterial Chemoembolization and Factors Affecting Patients Prognosis. J Vasc Interv Radiol. 2007;18(5):611-9;quiz 620. https://doi.org/10.1016/j.jvir.2007.02.023. PMID: 17494842.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zhengxiao L, Zhifang C, Shejiao D, et al. Cutaneous Necrosis Associated with Transcatheter Arterial Chemoembolization of the Intercostal Artery. J Vasc Interv Radiol. 2014;25(7):1141-3. e1. https://doi.org/10.1016/j.jvir.2013.12.018. PMID: 24968729.</mixed-citation><mixed-citation xml:lang="en">Zhengxiao L, Zhifang C, Shejiao D, et al. Cutaneous Necrosis Associated with Transcatheter Arterial Chemoembolization of the Intercostal Artery. J Vasc Interv Radiol. 2014;25(7):1141-3. e1. https://doi.org/10.1016/j.jvir.2013.12.018. PMID: 24968729.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hyun D, Cho SK, Shin SW, et al. Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020;43(4):587-96. https://doi.org/10/1007/s00270-019-02405-4. PMID: 31912214.</mixed-citation><mixed-citation xml:lang="en">Hyun D, Cho SK, Shin SW, et al. Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020;43(4):587-96. https://doi.org/10/1007/s00270-019-02405-4. PMID: 31912214.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Miyayama S, Matsui O, Nishida H, et al. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma fed by the cystic artery. J Vasc Interv Radiol. 2003;14(9Pt1):1155-61. https://doi.org/10.1097/01.rvi.0000086534.86489.10. PMID: 14514807.</mixed-citation><mixed-citation xml:lang="en">Miyayama S, Matsui O, Nishida H, et al. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma fed by the cystic artery. J Vasc Interv Radiol. 2003;14(9Pt1):1155-61. https://doi.org/10.1097/01.rvi.0000086534.86489.10. PMID: 14514807.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chu HH, Kim H-C, Chung JW, et al. Repeated Intra-Arterial Therapy via the Cystic Artery for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37(5);1283-91. https://doi.org/10.1007/s00270-013-0795-8. PMID: 24271841.</mixed-citation><mixed-citation xml:lang="en">Chu HH, Kim H-C, Chung JW, et al. Repeated Intra-Arterial Therapy via the Cystic Artery for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37(5);1283-91. https://doi.org/10.1007/s00270-013-0795-8. PMID: 24271841.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Miyayama S, Matsui O, Akakura Y, et al. Hepatocellular Carcinoma with Blood Supply from Omental Branches: Treatment with Transcatheter Arterial Embolization. J Vasc Interv Radiol. 2001;12(11):1285-90. https://doi.org/10.1016/s1051-0443(07)61553-x. PMID: 11698627.</mixed-citation><mixed-citation xml:lang="en">Miyayama S, Matsui O, Akakura Y, et al. Hepatocellular Carcinoma with Blood Supply from Omental Branches: Treatment with Transcatheter Arterial Embolization. J Vasc Interv Radiol. 2001;12(11):1285-90. https://doi.org/10.1016/s1051-0443(07)61553-x. PMID: 11698627.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jia Z, Tian F, Li S, et al. Supplemental transcatheter arterial chemoembolization for hepatocellular carcinoma fed by collateral omental artery. Hepatogastroenterology. 2014;61(135):2042-6. PMID:25713908.</mixed-citation><mixed-citation xml:lang="en">Jia Z, Tian F, Li S, et al. Supplemental transcatheter arterial chemoembolization for hepatocellular carcinoma fed by collateral omental artery. Hepatogastroenterology. 2014;61(135):2042-6. PMID:25713908.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Won JY, Lee DY, Lee JT, et al. Supplemental transcatheter arterial chemoembolization through a collateral omental artery: treatment for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2003;26(2);136-40. https://doi.org/10.1007/s00270-002-2629-y. PMID: 12638036.</mixed-citation><mixed-citation xml:lang="en">Won JY, Lee DY, Lee JT, et al. Supplemental transcatheter arterial chemoembolization through a collateral omental artery: treatment for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2003;26(2);136-40. https://doi.org/10.1007/s00270-002-2629-y. PMID: 12638036.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Triantafyllou K, Gkoflakis P, Grainek IM, et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2021;53(8):850-68. https://doi.org/10.1055/a-1496-8969. PMID: 34062566.</mixed-citation><mixed-citation xml:lang="en">Triantafyllou K, Gkoflakis P, Grainek IM, et al. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2021;53(8):850-68. https://doi.org/10.1055/a-1496-8969. PMID: 34062566.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Sengupta N, Feuerstein JD, Jairath V, et al. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. Am J Gastroenterol. 2023;118(2):208-31. https://doi.org/10.14309/aig.0000000000002130. PMID: 36535555.</mixed-citation><mixed-citation xml:lang="en">Sengupta N, Feuerstein JD, Jairath V, et al. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. Am J Gastroenterol. 2023;118(2):208-31. https://doi.org/10.14309/aig.0000000000002130. PMID: 36535555.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, An S, et al. Transarterial Chemoembolization of a Colic Branch of the Superior Mesenteric Artery in Patients with Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol. 2011;22(1):47-54. https://doi.org/10.1016/j.jvir2010.09.13. PMID: 21195900.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, An S, et al. Transarterial Chemoembolization of a Colic Branch of the Superior Mesenteric Artery in Patients with Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol. 2011;22(1):47-54. https://doi.org/10.1016/j.jvir2010.09.13. PMID: 21195900.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon UB, Lee JW, Baik SK, et al. Hepatocellular carcinoma supplied from the short gastric artery: treatment with chemoembolization. Cardiovasc Intervent Radiol. 2012;35(6):1512-4. https://doi.org/10.1007/s00270-012-0390. PMID: 22532333.</mixed-citation><mixed-citation xml:lang="en">Jeon UB, Lee JW, Baik SK, et al. Hepatocellular carcinoma supplied from the short gastric artery: treatment with chemoembolization. Cardiovasc Intervent Radiol. 2012;35(6):1512-4. https://doi.org/10.1007/s00270-012-0390. PMID: 22532333.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chung JW, Kim HC, Yoon JH, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. Korean J Radiol. 2006;7(4):257-66. https://doi.org/10.3348/kjr.2006.7.4.257. PMID: 17143029.</mixed-citation><mixed-citation xml:lang="en">Chung JW, Kim HC, Yoon JH, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. Korean J Radiol. 2006;7(4):257-66. https://doi.org/10.3348/kjr.2006.7.4.257. PMID: 17143029.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ishikawa M, Yamagami T, Kakizawa H, et al. Transarterial therapy of hepatocellular carcinoma fed by the right renal capsular artery. J Vasc Interv Radiol. 2014;25(3):389-95. https://doi.org/10.1016/j.jvir2013.11.009. PMID: 24581462.</mixed-citation><mixed-citation xml:lang="en">Ishikawa M, Yamagami T, Kakizawa H, et al. Transarterial therapy of hepatocellular carcinoma fed by the right renal capsular artery. J Vasc Interv Radiol. 2014;25(3):389-95. https://doi.org/10.1016/j.jvir2013.11.009. PMID: 24581462.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Chung JW, Park JH, Han JK, et al. Transcatheter Oily Chemoembolization of the Inferior Phrenic Artery in Hepatocellular Carcinoma: The Safety and Potential Therapeutic Role. J Vasc Interv Radiol. 1998;9(3):495-500. https://doi.org/10.1016/s1051-0443(98)70306-9. PMID: 9618112.</mixed-citation><mixed-citation xml:lang="en">Chung JW, Park JH, Han JK, et al. Transcatheter Oily Chemoembolization of the Inferior Phrenic Artery in Hepatocellular Carcinoma: The Safety and Potential Therapeutic Role. J Vasc Interv Radiol. 1998;9(3):495-500. https://doi.org/10.1016/s1051-0443(98)70306-9. PMID: 9618112.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Jia Z, Tu J, et al. Supplemental conventional transarterial embolization/chemoembolization therapy via extrahepatic arteries for hepatocellular carcinoma. J Cancer Res Ther. 2017;13(4):720-4. https://doi.org/10.4103/jcrt.JCRT_993_16. PMID: 28901321.</mixed-citation><mixed-citation xml:lang="en">Huang Y, Jia Z, Tu J, et al. Supplemental conventional transarterial embolization/chemoembolization therapy via extrahepatic arteries for hepatocellular carcinoma. J Cancer Res Ther. 2017;13(4):720-4. https://doi.org/10.4103/jcrt.JCRT_993_16. PMID: 28901321.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Chiu S-H, Chang P-Y, Shih Y-L, et al. Efficasy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Tretment for Unresectable Hepatocellular Carcinoma. Drug Des Devel Ther. 2020;14:5029-41. https://doi.org/10.2147/DDDT.S266470. PMID: 33235441.</mixed-citation><mixed-citation xml:lang="en">Chiu S-H, Chang P-Y, Shih Y-L, et al. Efficasy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Tretment for Unresectable Hepatocellular Carcinoma. Drug Des Devel Ther. 2020;14:5029-41. https://doi.org/10.2147/DDDT.S266470. PMID: 33235441.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y, Fang Z, Luo J, et al. Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent group in a single center. Exp Ther Med. 2015;10(6):2366-74. https://doi.org/10.3892/etm.2015.2822. PMID: 26668643.</mixed-citation><mixed-citation xml:lang="en">Zhao Y, Fang Z, Luo J, et al. Evaluation of extrahepatic collateral arteries in hepatocellular carcinoma in three independent group in a single center. Exp Ther Med. 2015;10(6):2366-74. https://doi.org/10.3892/etm.2015.2822. PMID: 26668643.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gokan T, Hashimoto T, Matsui S, et al. Helical CT demonstration of dilated right inferior phrenic arteries as extrahepatic collateral arteries of hepatocellular carcinomas. J Comput Assist Tomogr. 2001;25(1):68-73. https://doi.org/10.1097/00004728-200101000-00012. PMID: 11176296.</mixed-citation><mixed-citation xml:lang="en">Gokan T, Hashimoto T, Matsui S, et al. Helical CT demonstration of dilated right inferior phrenic arteries as extrahepatic collateral arteries of hepatocellular carcinomas. J Comput Assist Tomogr. 2001;25(1):68-73. https://doi.org/10.1097/00004728-200101000-00012. PMID: 11176296.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Abou Khadrah RS, Abedelmalik MH, Elhameed Alameldeen MA, Elbarbary AA. Hepatocellular carcinoma vascularization: CT angiography variations identifying arteries feeding the tumour. Egypt J Radiol Nucl Med. 2023;54:183. https://doi.org/10.1186/s43055-023-01133-7.</mixed-citation><mixed-citation xml:lang="en">Abou Khadrah RS, Abedelmalik MH, Elhameed Alameldeen MA, Elbarbary AA. Hepatocellular carcinoma vascularization: CT angiography variations identifying arteries feeding the tumour. Egypt J Radiol Nucl Med. 2023;54:183. https://doi.org/10.1186/s43055-023-01133-7.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC — Current State of the Art. Diagnostics(Basel). 2015;5(4):513-45. https://doi.org/10.3390/diagnostics5040513. PMID: 26854169.</mixed-citation><mixed-citation xml:lang="en">Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC — Current State of the Art. Diagnostics(Basel). 2015;5(4):513-45. https://doi.org/10.3390/diagnostics5040513. PMID: 26854169.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Tacher V, Radaelli A, Lin MD, Geschwind J-F. How I do it: Cone-Beam CT during transarterial Chemoembolization for Liver Cancer. Radiology. 2015;274(2):320-34. https://doi.org/10.1148/radiol.14131925. PMID: 25625741.</mixed-citation><mixed-citation xml:lang="en">Tacher V, Radaelli A, Lin MD, Geschwind J-F. How I do it: ConeBeam CT during transarterial Chemoembolization for Liver Cancer. Radiology. 2015;274(2):320-34. https://doi.org/10.1148/radiol.14131925. PMID: 25625741.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Lucatelli P, Corona M, Argiro R, et al. Impact of 3D Rotational Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol. 2015;38(3):523‑35. https://doi.org/10.1007/s00270-014-1023-x. PMID: 25488820.</mixed-citation><mixed-citation xml:lang="en">Lucatelli P, Corona M, Argiro R, et al. Impact of 3D Rotational Angiography on Liver Embolization Procedures: Review of Technique and Applications. Cardiovasc Intervent Radiol. 2015;38(3):523‑35. https://doi.org/10.1007/s00270-014-1023-x. PMID: 25488820.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Долгушин БИ, Таразов ПГ, Погребняков ИВ и др. Стандарты проведения процедуры трансартериальной химиоэмболизации при лечении пациентов с гепатоцеллюлярной карциномой. Москва, 2024.</mixed-citation><mixed-citation xml:lang="en">Dolgushin BI, Tarazov PG, Pogrebniakov IV, et al. Standarts for transarterial chemoembolization procedure in the treatment of patients with hepatocellular carcinoma. Moscow, 2024. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Балахнин ПВ, Беляев АМ, Багненко СС и др. Технологии плоскодетекторной компьютерной томографии в интервенционной онкологии: диагностика, стадирование и лечение гепатоцеллюлярного рака. Медицина высоких технологий. 2023;1(1):6-25.</mixed-citation><mixed-citation xml:lang="en">Balaknin PV, Belyaev AM, Bagnenko SS, et al. Flat-detector computed tomography technologies in interventional oncology: diagnosis, staging and treatment of hepatocellular carcinoma. High-Tech Medicine. 2023;1(1):6-25. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, Lee IJ, et al. Intercostal artery supplying hepatocellular carcinoma: demonstration of a tumor feeder by C-arm CT and multidetector row CT. Cardiovasc Intervent Radiol. 2011;34(1):87-91. https://doi.org/10.1007/s00270-010-9883-1. PMID: 20458586.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, Lee IJ, et al. Intercostal artery supplying hepatocellular carcinoma: demonstration of a tumor feeder by C-arm CT and multidetector row CT. Cardiovasc Intervent Radiol. 2011;34(1):87-91. https://doi.org/10.1007/s00270-010-9883-1. PMID: 20458586.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H-C, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of right inferior phrenic artery with C-arm CT. J Vasc Interv Radiol. 2009;20(7):888-95. https://doi.org/10.1016/j.jvir.2009.03.036. PMID: 19481471.</mixed-citation><mixed-citation xml:lang="en">Kim H-C, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of right inferior phrenic artery with C-arm CT. J Vasc Interv Radiol. 2009;20(7):888-95. https://doi.org/10.1016/j.jvir.2009.03.036. PMID: 19481471.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Малькевич ВИ, Балахнин ПВ, Шмелев АС и др. Коллатеральный кровоток и паразитарное кровоснабжение опухоли как возможная причина неэффективности трансартериальной химиоэмболизации при лечении гепатоцеллюлярного рака. Клинический случай в онкологии. 2025;3(1):53-61. https://doi.org/10.62546/3034-1477-2025-3-1-53-61.</mixed-citation><mixed-citation xml:lang="en">Malkevich VI, Balakhnin PV, Shmelev AS, et al. Collateral blood flow and parasitic blood supply to the tumor as a possible cause of ineffectiveness of transarterial chemoembolization in the treatment of hepatocellular cancer. Clinical Сase in Оncology. 2025;3(1):53-61. (In Russ.). https://doi.org/10.62546/3034-1477-2025-3-1-53-61.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Lokken RP, Fidelman N, Kolli KP, Kerlan Jr RK. Safety and Efficasy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries. J Vasc Interv Radiol. 2016;27(11):1698-1704. https://doi.org/10.1016/j.jvir.2016.04.034. PMID: 27397617.</mixed-citation><mixed-citation xml:lang="en">Lokken RP, Fidelman N, Kolli KP, Kerlan Jr RK. Safety and Efficasy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries. J Vasc Interv Radiol. 2016;27(11):1698-1704. https://doi.org/10.1016/j.jvir.2016.04.034. PMID: 27397617.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol. 2024;42(15):1830-50. https://doi.org/10.1200/JCO.23.02745. PMID: 38502889.</mixed-citation><mixed-citation xml:lang="en">Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol. 2024;42(15):1830-50. https://doi.org/10.1200/JCO.23.02745. PMID: 38502889.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https://www.annalsofoncology.org/article/S0923-7534(25)00073-0/fulltext https://doi.org/10.1016/j.annoc.2025.02.006.</mixed-citation><mixed-citation xml:lang="en">Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https://www.annalsofoncology.org/article/S0923-7534(25)00073-0/fulltext https://doi.org/10.1016/j.annoc.2025.02.006 .</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Бредер ВВ, Балахнин ПВ, Виршке ЭР и др. Практические рекомендации по лекарственному лечению больных гепатоцеллюлярным раком. Злокачественные опухоли: Практические рекомендации RUSSCO. 2021;11(3S2-1):431-51. https://doi.org/10.18027/2224-5057-2021-11-3S2-25.</mixed-citation><mixed-citation xml:lang="en">Breder VV, Balakhnin PV, Virshke ER, et al. Practical recommendations for drug treatment of patients with hepatocellular carcinoma. Malignant Tumours. 2021;11(3S2- 1):431-51. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-3S2-25.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
